

Bio

Dr. Daphna Laifenfeld is Head, Personalized Medicine and Diagnostics (PMD), at Teva's Global R&D, where she heads activities for defining the strategy, development plan, and delivery of personalized medicine solutions that increase probability of success and ensure meaningful and patient-centric design and interpretation of clinical trials, as well as in-market applications. This includes the clinical biomarker strategy and implementation through to commercial diagnostics. Daphna has dedicated her career to the field of personalized and translational medicine, with a focus on genomics and biomarker implementation through to diagnostic development, all toward the advancement of drug development patient health. In her current role she is charged with driving the application of robust and differentiated methodologies for disease characterization, patient selection, stratification and monitoring, bringing value to patients and health management.

Before joining Teva, Dr. Laifenfeld engaged in translational/biomarker development activities within the pipeline of multiple top-10 pharma, including Roche, GSK, Pfizer, as well as consumer product companies. She served several roles with increasing responsibility at Selventa, a system's biology company focused on personalized medicine, and was appointed as Global Head of Diagnostics, where she was responsible for the company's internal diagnostic development strategy, in addition to overseeing the multiple biomarker discovery programs.

In academia, Dr. Laifenfeld studied molecular pathways and pharmacogenomics in CNS, including a focus on the biology underlying Alzheimer's disease in Prof. Rachael Neve's lab at Harvard University, and on pharmacogenomics of Major Depression therapeutic response at Prof. Ehud Klein's lab at the Technion. Dr. Laifenfeld received her PhD from the Technion – Israel Institute of Technology.